Rogier AJ, Chen Y, Alali H, Dick TA, Coley JL, Wallach JV, Moniri NH, Canal CE.
Discovery and Structure-activity Relationship of Synthetic Cathinone-Derived Acetylcholine M2 Receptor Antagonists.
Journal of Pharmacology and Experimental Therapeutics. 392(3S):101331, 2025.
Teyani RL and Moniri NH.
Free-Fatty Acid Receptor-4 (FFA4/GPR120) modulates cholesterol-induced responses in macrophages.
Journal of Pharmacology and Experimental Therapeutics. 392(3S):100578, 2025.
Green AJ, Chitre N, Rambacher KM, Murnane KS, Moniri NH.
Probing the role of Free-Fatty Acid Receptor-4 (FFA4) as novel target for Parkinson’s Disease:
FFA4 agonists increase dopamine synthesis and reduce 6-OHDA-induced cell death.
Journal of Pharmacology and Experimental Therapeutics. 389(S3):148, 2024.
Hasan R, Ezewudo E, Zerin F, Menon S, Simon N, Moniri NH, Nguyen TT, Chougule MB, Rahman T.
Indole-3 acetic acid: a novel dual-action inhibitor of the endothelin system for treating hypertension.
Hypertension. 80:AP318, 2023.
Ezewudo E, Menon S, Zerin F, Moniri NH, Nguyen T, Kashikar R, Chougule M, Rahman T, Hasan R.
A novel small molecule inhibitor of vascular endothelin signaling and hypertension.
Physiology. 38:S1, 2023.
Moniri NH, Senatorov IS, Cheshmehkani A, Karmokar P, Singh K.
The skeletal muscle relaxer cyclobenzaprine is a potent non-competitive histamine H1 receptor antagonist.
The FASEB Journal. 35(S1), 2021.
Karmokar PF and Moniri NH.
Diverse Roles of G-Protein-Coupled Receptor 40 (GPR40/FFA1) and GPR120 (FFA4) in renal cell carcinoma.
The FASEB Journal. 35(S1), 2021.
Singh K and Moniri NH.
Differential modulation of β2AR mediated cAMP/PKA/CREB signaling in normal vs asthmatic airway cells.
The FASEB Journal. 35(S1), 2021.
Rambacher KM and Moniri NH.
Redox deficient cysteine residues impair β2-adrenergic receptor function.
The FASEB Journal. 33(S1):668.3, 2019.
Chitre NM, Wood B, Ray A, Moniri NH, Murnane KS.
Neuroprotective effects of docosahexaenoic acid in 6-OHDA Parkinsonism model.
The FASEB Journal. 33(S1):501.10, 2019.
Moniri NH and Sambunaris A.
Institute for Advanced Medical Research at Mercer University.
American Journal of Pharmaceutical Education. 82(5):25, 2018.
Rambacher KM and Moniri NH.
Ligand binding to β2-adrenergic receptor depends on oxidation state.
The FASEB Journal. 32(S1):555.14, 2018.
Senatorov IS, Cheshmehkani A, Moniri NH.
Phosphorylation differences in FFA4 isoforms.
The FASEB Journal. 32(S1):555.30, 2018.
Cheshmehkani A and Moniri NH.
FFA4 receptor mutants regulate COX-2 expression.
The FASEB Journal. 31(S1):992.10, 2018.
Spry R et al.
Motor and non-motor symptoms in 6-OHDA rat model.
The FASEB Journal. 31(S1):662.7, 2017.
Murnane KS et al.
Pharmacophore modeling of 5-HT2A biased agonism.
The FASEB Journal. 29:768.12, 2015.
Singh M and Moniri NH.
ROS in β2-adrenergic receptor signaling.
The FASEB Journal. 28:662.2, 2014.
Singh M and Moniri NH.
ROS in β2AR–β-arrestin signaling.
Molecular Biology of the Cell. 24(24):3775, 2013.
Burns RN and Moniri NH.
GPCR phosphorylation and oxidation studies.
The FASEB Journal. (multiple entries), 2010–2012.